<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03560986</url>
  </required_header>
  <id_info>
    <org_study_id>KF7013-04</org_study_id>
    <secondary_id>2017-004244-37</secondary_id>
    <secondary_id>U1111-1203-5020</secondary_id>
    <nct_id>NCT03560986</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Intravenous Neridronic Acid in Complex Regional Pain Syndrome (CRPS)</brief_title>
  <official_title>Placebo-controlled Efficacy and Safety Trial of Intravenous Neridronic Acid in Subjects With Complex Regional Pain Syndrome (CRPS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grünenthal GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grünenthal GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this trial was to investigate the efficacy and safety of intravenous neridronic&#xD;
      acid in subjects with Complex Regional Pain Syndrome (CRPS).&#xD;
&#xD;
      The trial consisted of an Enrollment Period lasting up to 60 days, Treatment Period A&#xD;
      consisting of 4 infusions (neridronic acid 100 mg or placebo) over 10 days, and a Follow-up&#xD;
      Period 1 until Week 26. At Week 26, participants meeting the pre-specified criteria entered&#xD;
      the open-label Treatment Period B with 4 additional infusions (neridronic acid) over 10 days&#xD;
      and follow-up visits until Week 52. Participants not meeting the pre-specified criteria to&#xD;
      continue into Treatment Period B continued in Follow-up Period 2 until Week 52.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor decision&#xD;
  </why_stopped>
  <start_date type="Actual">May 31, 2018</start_date>
  <completion_date type="Actual">August 1, 2019</completion_date>
  <primary_completion_date type="Actual">August 1, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Blinded treatment in Treatment Period A, open-label infusion in Treatment Period B.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline to Week 12 in the Average Pain Intensity Score (Weekly Average of Pain Values Recorded Daily in the Electronic Diary)</measure>
    <time_frame>From the Baseline Phase (Day -7 to Day -1) to Week 12</time_frame>
    <description>In the Baseline Phase and in Treatment Period A/Follow-up Period 1, participants were asked to assessed their average CRPS-related pain on an 11-point numerical rating scale (NRS) - from 0 = &quot;no pain&quot; to 10 = &quot;pain as bad as you can imagine&quot; and report it once daily (in the evening, 24-hour recall) in an electronic diary.&#xD;
Changes from baseline (average for the Baseline Phase) to the weekly average for Week 12 were calculated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 26 in the Average Pain Intensity Recorded on the Tablet Computer</measure>
    <time_frame>From baseline (Visit 2 [Day 1]) to Visit 11 (Week 26)</time_frame>
    <description>11-point NRS - from 0 = &quot;no pain&quot; to 10 = &quot;pain as bad as you can imagine&quot; - reported at the visits on a tablet computer (24-hour recall). Changes from baseline to Week 26 were planned to be analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Response to Treatment, Defined as at Least 30% Decrease From Baseline in the Average Pain Intensity at Week 12, Recorded on the Tablet Computer</measure>
    <time_frame>From baseline (Visit 2 [Day 1]) to Visit 8 (Week 12)</time_frame>
    <description>11-point NRS - from 0 = &quot;no pain&quot; to 10 = &quot;pain as bad as you can imagine&quot; - reported at the visits on a tablet computer (24-hour recall).&#xD;
The number of participants with response at Week 12 was planned to be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Response to Treatment, Defined as at Least 30% Decrease From Baseline in the Average Pain Intensity at Week 26, Recorded on the Tablet Computer</measure>
    <time_frame>From baseline (Visit 2 [Day 1]) to Visit 11 (Week 26)</time_frame>
    <description>11-point NRS - from 0 = &quot;no pain&quot; to 10 = &quot;pain as bad as you can imagine&quot; - reported at the visits on a tablet computer (24-hour recall). The number of participants with response at Week 26 was planned to be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 12 in the Pain Intensity Level of Dynamic Mechanical Allodynia (DMA)</measure>
    <time_frame>From baseline (Visit 2 [Day 1]) to Visit 8 (Week 12)</time_frame>
    <description>Dynamic mechanical allodynia: a tactile stimulus is applied in a single sweeping motion (1 cm to 2 cm length) on the skin on the affected limb. The participants are asked to judge the stimulus intensity by means of an NRS (0 to 10). &quot;0&quot; in this case means &quot;no pain&quot;. Each &quot;pricking&quot;, &quot;stinging&quot; or &quot;burning&quot; sensation is defined as a painful sensation, which should always be evaluated by giving a value greater than &quot;0&quot;. &quot;10&quot; corresponds to the individual maximum pain imaginable. Change from baseline was planned to analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 12 in the Pressure Pain Threshold (PPT) Ratio for the Thenar Muscle/Abductor Hallucis Muscle</measure>
    <time_frame>From baseline (Visit 2 [Day 1]) to Visit 8 (Week 12)</time_frame>
    <description>Pressure pain threshold: using a pressure algometer (contact area 1 cm2), the threshold for pressure-induced pain is measured on the thenar muscle/abductor hallucis muscle in 3 series of slowly increasing stimulus intensities (at a rate of about 50 kPa/s). The threshold is then determined as the arithmetic mean of the 3 series (in kPa).&#xD;
The ratio of the thresholds of the affected limb versus the unaffected limb was planned to be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 12 in the Ratio of the Figure of Eight Measurements of the Affected Limb Versus the Unaffected Limb</measure>
    <time_frame>From baseline (Visit 2 [Day 1]) to Visit 8 (Week 12)</time_frame>
    <description>In participants with the CRPS sign of edema on the CRPS severity score at baseline, circumference of the hand or foot will be measured by the investigator with measurement tape using the figure-of-eight method at both the affected limb and the contralateral unaffected limb. Each measurement will be performed 3 times. The average of the 3 measurements will be used for further analysis.&#xD;
The ratio of the averages of the affected limb versus the unaffected limb was planned to be calculated and used for the determination of the change from baseline.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">267</enrollment>
  <condition>Complex Regional Pain Syndrome (CRPS)</condition>
  <arm_group>
    <arm_group_label>Neridronic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neridronic acid 100 mg - 4 intravenous (i.v.) infusions within 10 days (i.e., on Days 1, 4, 7, and 10). The investigational medicinal product (IMP) was diluted in sterile normal saline to a volume of approximately 500 mL before slow administration.&#xD;
The maximum neridronic acid dose was 800 mg: 400 mg in Treatment Period A and 400 mg in Treatment Period B.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo - 4 intravenous infusions within 10 days (i.e., on Days 1, 4, 7, and 10). The IMP was diluted in sterile normal saline to a volume of approximately 500 mL before slow administration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neridronic acid 100 mg</intervention_name>
    <description>100 mg neridronic acid supplied in glass vials in 8 mL of excipients.</description>
    <arm_group_label>Neridronic acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Glass vials with matching placebo.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent signed.&#xD;
&#xD;
          -  Male or female participant at least 18 years of age at Visit 1.&#xD;
&#xD;
          -  A diagnosis of CRPS according to the clinical diagnostic criteria recommended by the&#xD;
             International Association for the Study of Pain (IASP; &quot;Budapest clinical criteria&quot;),&#xD;
             assessed at Visit 1. Signs and symptoms of CRPS must apply to an affected limb (arm or&#xD;
             leg) and must demonstrate asymmetry with respect to the contralateral limb. The CRPS&#xD;
             duration must be 2 years or less since onset of symptoms.&#xD;
&#xD;
          -  A baseline average pain intensity score of greater than or equal to 4 using an&#xD;
             11-point numerical rating scale (NRS), referring to the CRPS-affected limb (average of&#xD;
             pain recorded over 7 days). The baseline average pain intensity score will be&#xD;
             calculated automatically by the electronic diary, which must be checked prior to&#xD;
             allocation at Visit 2. A participant who has not met average baseline pain intensity&#xD;
             requirements (at least 4 average pain intensity ratings) due to lack of compliance&#xD;
             with the electronic diary may be rescheduled for Visit 2 (1 time only), with&#xD;
             appropriate re-training to ensure compliance with use of the electronic diary.&#xD;
&#xD;
          -  In stable treatment and follow-up therapy for CRPS for at least 1 month prior to&#xD;
             allocation to treatment (Visit 2). Participants must have failed attempts with at&#xD;
             least 2 available treatments for CRPS, 1 of which must have been a pharmacologic&#xD;
             treatment.&#xD;
&#xD;
          -  Women of child-bearing potential must have a negative urine Beta-human chorionic&#xD;
             gonadotropin (ß-HCG) pregnancy test at Visit 1 and must be using 2 forms of medically&#xD;
             acceptable contraception, including at least 1 highly effective method of&#xD;
             contraception with a low failure rate, defined as less than 1% per year, and a second&#xD;
             medically acceptable method such as use of condoms with spermicide by their male&#xD;
             partner. A barrier method alone is not acceptable. Highly effective methods of&#xD;
             contraception must be used for at least 1 month prior to Visit 2 and for the duration&#xD;
             of the trial. Male participants must use condom and spermicide during intercourse and&#xD;
             must take care that the female sexual partner uses at least 1 additional method of&#xD;
             contraception with a low failure rate defined as above, starting with Visit 2 until at&#xD;
             least 4 weeks after the last Investigational medicinal product (IMP) infusion.&#xD;
&#xD;
          -  Participants must be able to communicate meaningfully, be able to differentiate with&#xD;
             regard to location and intensity of the pain, and be able to answer the questions in&#xD;
             the questionnaires used in this trial (assistance in filling out the questionnaires&#xD;
             may be provided, if required due to motor or other physical impairment).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of renal impairment (estimated Glomerular Filtration Rate [eGFR] less than 30&#xD;
             mL/min/1.73 m2 using the 2009 Chronic Kidney Disease Epidemiology Collaboration&#xD;
             [CKD-EPI] creatinine equation [Levey et al. 2009] or a urinary albumin to creatinine&#xD;
             ratio [ACR] greater than 150 mg/g), based on central safety laboratory data obtained&#xD;
             prior to Visit 2. Note: a single repeat laboratory test is allowed.&#xD;
&#xD;
          -  Serum calcium or magnesium outside of the central laboratory's reference range, based&#xD;
             on central safety laboratory data obtained prior to Visit 2 (a single repeat&#xD;
             laboratory test is allowed); a history of hypocalcemia or a metabolic disorder&#xD;
             anticipated to increase risk for hypocalcemia (e.g., hypoparathyroidism); anticipated&#xD;
             need for any new drug with known potential to cause hypocalcemia (e.g.,&#xD;
             aminoglycosides, new treatment with or dose adjustment of loop diuretics) during the&#xD;
             trial. Participants on a stable dose of loop diuretics may receive treatment with IMP&#xD;
             as long as no dosage increases in the diuretic medication are anticipated and calcium&#xD;
             levels are in the reference range.&#xD;
&#xD;
          -  Vitamin D deficiency, defined as a 25(OH)D level less than 30 ng/mL (75 nmol/L), based&#xD;
             on central safety laboratory data obtained prior to Visit 2 (up to 4 repeat laboratory&#xD;
             tests are allowed). Participants with vitamin D deficiency should receive appropriate&#xD;
             supplementation during the Enrollment Period. A vitamin D level of at least 30 ng/mL&#xD;
             (75 nmol/L) must be documented prior to allocation to IMP.&#xD;
&#xD;
          -  Corrected QT interval (according to Fridericia's formula; QTcF) greater than 470 ms&#xD;
             (average of 3 Electrocardiogram (ECGs) obtained at Visit 1) according to central ECG&#xD;
             reading facility evaluation or QTcF greater than 470 ms at pre-dose ECG at Visit 2&#xD;
             according to the investigator's judgment; serum potassium outside the central&#xD;
             laboratory's reference range at Visit 1(a single repeat laboratory test is allowed);&#xD;
             clinically unstable cardiac disease, including: unstable atrial fibrillation,&#xD;
             symptomatic bradycardia, unstable congestive heart failure, active myocardial&#xD;
             ischemia, or an indwelling pacemaker; evidence of complete left bundle branch block;&#xD;
             complete atrioventricular block; history of Long QT Syndrome or a relative with this&#xD;
             condition; or any history of or other known risk factor for torsade de pointes.&#xD;
&#xD;
          -  Participants receiving medications with a known risk of torsades de pointes within 7&#xD;
             days prior to allocation. Participants receiving selective serotonin re-uptake&#xD;
             inhibitor antidepressants are eligible if the QT interval values do not meet the&#xD;
             exclusion criteria, the medication was started at least 1 month prior to allocation,&#xD;
             the dose is stable, and the dose is anticipated to remain stable throughout the trial.&#xD;
&#xD;
          -  Any prior use of a bisphosphonate for treatment of CRPS, any prior administration of a&#xD;
             bisphosphonate within the previous year, anticipated requirement for treatment with a&#xD;
             bisphosphonate for another condition such as osteoporosis during the trial, or&#xD;
             administration of denosumab (Prolia®) or other bone turnover suppressing drugs within&#xD;
             6 months prior to Visit 1.&#xD;
&#xD;
          -  History of any allergic or hypersensitivity reaction to neridronic acid or other&#xD;
             bisphosphonate, acetaminophen, or to vitamin D or calcium supplements.&#xD;
&#xD;
          -  Recent tooth extraction or other invasive dental procedure (within 3 months prior to&#xD;
             Visit 1), unhealed or infected extraction site, or significant dental/periodontal&#xD;
             disease that may pre-dispose to need for tooth extraction or other invasive dental&#xD;
             procedures during the trial. Participants with indeterminate, suspicious or unreliable&#xD;
             dental history, in the opinion of the investigator, must undergo a dental examination&#xD;
             prior to receiving treatment.&#xD;
&#xD;
          -  Evidence of denture-related gum trauma or improperly fitting dentures causing injury.&#xD;
&#xD;
          -  Prior radiation therapy of the head or neck (within 1 year of Visit 1).&#xD;
&#xD;
          -  History of malignancy within 2 years prior to Visit 1, with the exception of basal&#xD;
             cell carcinoma.&#xD;
&#xD;
          -  Use of nerve blocks, ketamine infusions, intravenous immunoglobulin, acupuncture,&#xD;
             electromagnetic field treatment, or initiation/implementation of radiofrequency&#xD;
             ablation or other sympathectomy procedures, or peripheral nerve stimulation within 6&#xD;
             weeks prior to Visit 1.&#xD;
&#xD;
          -  Evidence of current alcohol or drug abuse, or history of alcohol or drug abuse within&#xD;
             2 years of Visit 1, based on participant history and physical examination and&#xD;
             according to the investigator's judgment.&#xD;
&#xD;
          -  Any other severe medical condition, including severe depression, or any other severe&#xD;
             mood disorder, that in the opinion of the investigator may affect efficacy or safety&#xD;
             assessments or may compromise the participants safety during trial participation.&#xD;
&#xD;
          -  Women who are pregnant or breastfeeding.&#xD;
&#xD;
          -  Elevated aspartate aminotransferase or alanine aminotransferase greater than 2-fold&#xD;
             upper limit of normal, based on central safety laboratory data obtained at Visit 1, or&#xD;
             current evidence of chronic liver disease. Safety laboratory testing may be repeated&#xD;
             prior to Visit 2, and participants will be allowed in the trial if results of 2&#xD;
             consecutive tests, at least 3 days apart, are less than or equal to 2-fold upper limit&#xD;
             of normal.&#xD;
&#xD;
          -  Participation in another investigational drug trial within 3 months prior to Visit 1,&#xD;
             or any previous trial involving neridronic acid, with the exception of participants&#xD;
             participating in study KF7013-01 who were assigned to placebo and did not receive&#xD;
             neridronic acid.&#xD;
&#xD;
          -  Participant is engaged in litigation related to their disability from CRPS in which&#xD;
             monetary gain or loss (or other compensation) may affect their objective participation&#xD;
             in the trial.&#xD;
&#xD;
          -  Participants taking forbidden concomitant medications/therapies or not being able to&#xD;
             follow the rules of use of concomitant treatment.&#xD;
&#xD;
          -  Participants incapable of giving informed consent.&#xD;
&#xD;
        Criteria to continue into Treatment Period B&#xD;
&#xD;
          -  A value of at least 4 on the pain intensity question (question number 29, GLOBAL07) of&#xD;
             the Patient-Reported Outcomes Measurement Information System (PROMIS®) (PROMIS-29&#xD;
             profile) at Visit 11.&#xD;
&#xD;
          -  The following exclusion criteria are not met:&#xD;
&#xD;
               -  Evidence of renal impairment (eGFR less than 30 mL/min/1.73 m2 using the 2009&#xD;
                  CKD-EPI creatinine equation [Levey et al. 2009] or a urinary ACR greater than 150&#xD;
                  mg/g), based on central safety laboratory data obtained prior to Visit 11. A&#xD;
                  single repeat laboratory test is allowed.&#xD;
&#xD;
               -  Corrected QT interval (QTcF) greater than 470 ms (average of 3 ECGs obtained at&#xD;
                  Visit 10) according to the central ECG reading facility evaluation or QTcF&#xD;
                  greater than 470 ms at pre-dose ECG at Visit 11 according to the investigator's&#xD;
                  judgment; serum potassium outside the central laboratory's reference range at&#xD;
                  Visit 10 (a single repeat laboratory test is allowed); clinically unstable&#xD;
                  cardiac disease, including: unstable atrial fibrillation, symptomatic&#xD;
                  bradycardia, unstable congestive heart failure, active myocardial ischemia, or an&#xD;
                  indwelling pacemaker; evidence of complete left bundle branch block; complete&#xD;
                  atrioventricular block; any other known risk factor for torsade de pointes.&#xD;
&#xD;
               -  Participants receiving medications with a known risk of torsades de pointes&#xD;
                  within 7 days prior to re-allocation.&#xD;
&#xD;
               -  Participants taking forbidden concomitant medications/therapies or not being able&#xD;
                  to follow the rules of use of concomitant treatment.&#xD;
&#xD;
               -  Recent tooth extraction or other invasive dental procedure (within 3 months prior&#xD;
                  to Visit 11), unhealed or infected extraction site, or significant&#xD;
                  dental/periodontal disease that may pre-dispose to need for tooth extraction or&#xD;
                  other invasive dental procedures during the further course of the trial.&#xD;
&#xD;
               -  Serum calcium outside of the central laboratory's reference range, despite&#xD;
                  appropriate supplementation between Visit 10 and Visit 11, based on the last&#xD;
                  central safety laboratory data obtained prior to Visit 11. Two repeat laboratory&#xD;
                  tests are allowed.&#xD;
&#xD;
               -  Vitamin D deficiency prior to IMP re-allocation, defined as a 25(OH)D level less&#xD;
                  than 30 ng/mL (75 nmol/L), based on the last central safety laboratory data&#xD;
                  obtained prior to Visit 11, i.e., inability to normalize 25(OH)D levels to at&#xD;
                  least 30 ng/mL (75 nmol/L) despite appropriate supplementation between Visit 10&#xD;
                  and Visit 11. Two repeat laboratory tests are allowed.&#xD;
&#xD;
               -  Elevated aspartate aminotransferase or alanine aminotransferase greater than&#xD;
                  2-fold upper limit of normal, based on central safety laboratory data obtained at&#xD;
                  Visit 10, or current evidence of chronic liver disease. A single repeat&#xD;
                  laboratory test is allowed.&#xD;
&#xD;
          -  No other criterion for trial and/or IMP discontinuation is met.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Grünenthal Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Grünenthal GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>US446 - Clinical Trial Connection</name>
      <address>
        <city>Cottonwood</city>
        <state>Arizona</state>
        <zip>86326</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US453 - Physicians Research Group II, LLC</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85284</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US428 - Quality of Life Medical and Research Center LLC</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US422 - Woodland International Research Group</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US454 - Alliance Research Institute</name>
      <address>
        <city>Canoga Park</city>
        <state>California</state>
        <zip>91304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US415 - Clearview Medical Research LLC</name>
      <address>
        <city>Canyon Country</city>
        <state>California</state>
        <zip>91351</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US410 - Alliance Research Centers</name>
      <address>
        <city>Laguna Hills</city>
        <state>California</state>
        <zip>92653</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US432 - Torrance Clinical Research Institute Inc.</name>
      <address>
        <city>Lomita</city>
        <state>California</state>
        <zip>90717</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Us414 - Alexander Ford Md</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US441 - Samaritan Center for Medical Research</name>
      <address>
        <city>Los Gatos</city>
        <state>California</state>
        <zip>95032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US406 - CI Trials</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US411 - Syrentis Clinical Research</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US420 - Mountain View Clinical Research, INC</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US447 - ASCLEPES Research Centers</name>
      <address>
        <city>Brooksville</city>
        <state>Florida</state>
        <zip>34613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US457 - Florida Spine Institute</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US430 - South Lake Pain Institute</name>
      <address>
        <city>Clermont</city>
        <state>Florida</state>
        <zip>34711</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US434 - Finlay Medical Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US407 - Oceane 7 Medical and Research Center, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US436 - Cordova Research Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US417 - Tampa Pain Relief Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US403 - Palm Beach Research Center</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US404 - Infinite Clinical Trials</name>
      <address>
        <city>Riverdale</city>
        <state>Georgia</state>
        <zip>30274</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US424 - Georgia Neurology and Sleep Medicine Assoc.</name>
      <address>
        <city>Suwanee</city>
        <state>Georgia</state>
        <zip>30024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US431 - Injury Care Research, LLC</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US437 - Great Lakes Clinical Trials LLC</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60640</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US435 - Centex Studies Inc</name>
      <address>
        <city>Lake Charles</city>
        <state>Louisiana</state>
        <zip>70601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US448 - The Center for Rheumatology and Bone Research</name>
      <address>
        <city>Wheaton</city>
        <state>Maryland</state>
        <zip>20902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US450 - SRI International</name>
      <address>
        <city>Plymouth</city>
        <state>Michigan</state>
        <zip>48170</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US449 - Michigan Pain Consultants</name>
      <address>
        <city>Wyoming</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US433 - Creighton University - Osteoporosis Research Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US419 - Manhattan Behavioral Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US440 - OnSite Clinical Solutions LLC</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US405 - OnSite Clinical Solutions LLC</name>
      <address>
        <city>Hickory</city>
        <state>North Carolina</state>
        <zip>28601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US416 - Medical Research International</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US429 - Lehigh Valley Health</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US438 - Abington Neurological Associates, LTD.</name>
      <address>
        <city>Willow Grove</city>
        <state>Pennsylvania</state>
        <zip>19090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US425 - PCPMG Clinical Research Unit LLC</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US423 - Biopharma Informatic Inc. Research Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US443 - Centex Studies Inc</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77058</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US421 - Northwest Clinical Research Center</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US445 - Exemplar Research Inc</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CA404 - Jeffrey Weinberg Medicine Professional Corporation c/o Jacobs Pain Center</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <zip>L3R 9W9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CA406 - Malton Medical Centre (attn: Vrijender Singh)</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L4V 1P1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CA402 - SKDS Research Inc</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 5G8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CA407 - King Street Medical Clinic</name>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <zip>L1H 1G6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CA403 - Bluewater Clinical Research Group</name>
      <address>
        <city>Sarnia</city>
        <state>Ontario</state>
        <zip>N7T 4X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CA405 - Canadian Centre for Clinical TrialsCCCT</name>
      <address>
        <city>Thornhill</city>
        <state>Ontario</state>
        <zip>L4J 1W3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CZ403 - CCBR Ostrava</name>
      <address>
        <city>Ostrava</city>
        <zip>70 200</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CZ402 - CCR Czech a,s.</name>
      <address>
        <city>Pardubice</city>
        <zip>53 002</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CZ401 - FORBELI s.r.o.</name>
      <address>
        <city>Prague 6</city>
        <zip>16 000</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PL405 - Medical Solutions</name>
      <address>
        <city>Elblag</city>
        <zip>82-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PL404 - Zagiel Med Sp Zoo</name>
      <address>
        <city>Lublin</city>
        <zip>20-362</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PL403 - Alergo-Med Specjalistyczna Przychodnia Lekarska Sp.z o.o</name>
      <address>
        <city>Tarnów</city>
        <zip>33-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RS401 - Clinical Center of Serbia, Clinic for physical medicine and rehabilitation</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RS403 - Clinical Center Kragujevac, Department of Physical Medicine and rehabilitation</name>
      <address>
        <city>Kragujevac</city>
        <zip>34000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RS404 - Clinical Center Nis, Clinic for Physical Medicine and Rehabilitation</name>
      <address>
        <city>Nis</city>
        <zip>18000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RS405 - Clinical Center of Vojvodina, Medical Rehabilitation Clinic</name>
      <address>
        <city>Novi Sad</city>
        <zip>21000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SK402 - MUDr. Beata Dupejova, neurologicka ambulancia sro</name>
      <address>
        <city>Banska Bystrica</city>
        <zip>97404</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SK404 - Medical Center Konzilium</name>
      <address>
        <city>Dubnica nad Vahom</city>
        <zip>018 41</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SK403 - NEURES, s.r.o.</name>
      <address>
        <city>Krompachy</city>
        <zip>5342</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SK401 - MUDr. Viliam Cíbik, PhD, Algeziologická ambulancia</name>
      <address>
        <city>Pruske</city>
        <zip>1852</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GB413 - MAC Clinical Research</name>
      <address>
        <city>Barnsley</city>
        <zip>S75 3DL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GB412 - MAC Clinical Research</name>
      <address>
        <city>Blackpool</city>
        <zip>FY2 0JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GB415 - MAC Clinical Research</name>
      <address>
        <city>Cannock</city>
        <zip>WS11 0BN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GB416 - Royal Devon and Exeter Hospital</name>
      <address>
        <city>Exeter</city>
        <zip>EX2 5DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GB410 - MAC Clinical Research</name>
      <address>
        <city>Leeds</city>
        <zip>LS10 1DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GB409 - MAC Clinical Research</name>
      <address>
        <city>Liverpool</city>
        <zip>L34 1BH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GB407 - Pain and Neuromodulation Centre Ground Floor, Gassiot House, St Thomas Hospital</name>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GB402 - St Pancras Clinical Research</name>
      <address>
        <city>London</city>
        <zip>WC1X 8QD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GB408 - MAC Clinical Research</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9NQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GB414 - MAC Clinical Research</name>
      <address>
        <city>Stockton-on-Tees</city>
        <zip>TS17 6EW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Poland</country>
    <country>Serbia</country>
    <country>Slovakia</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009 May 5;150(9):604-12. Erratum in: Ann Intern Med. 2011 Sep 20;155(6):408.</citation>
    <PMID>19414839</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 7, 2018</study_first_submitted>
  <study_first_submitted_qc>June 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2018</study_first_posted>
  <results_first_submitted>May 12, 2020</results_first_submitted>
  <results_first_submitted_qc>July 20, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 5, 2020</results_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neridronic Acid</keyword>
  <keyword>Neridronate</keyword>
  <keyword>CRPS</keyword>
  <keyword>Reflex sympathetic dystrophy (RSD)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Complex Regional Pain Syndromes</mesh_term>
    <mesh_term>Reflex Sympathetic Dystrophy</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Somatoform Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Information available on the Grünenthal Group Web Site (see URL below for details); according to the European Federation of Pharmaceutical Industries and Associations (EFPIA) Data Sharing Principles.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_url>http://www.grunenthal.com/r-d-vision-mission/clinical-trials/data-sharing-clinical-trials</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan: Final-Analysis-KF7013-04</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 11, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/86/NCT03560986/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan: Pooled-Interim-Analysis-KF7013-02-KF7013-04</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 3, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/86/NCT03560986/SAP_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 22, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/86/NCT03560986/Prot_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First participant enrollment on 31 May 2018. After a pooled interim analysis of primary endpoint data of studies KF7013-04 and KF7013-02 (NCT03530345), recruitment was stopped as interim results indicated futility. Last participant's last assessment was on 01 Aug 2019.</recruitment_details>
      <pre_assignment_details>267 participants were enrolled (signed consent), 100 were allocated to treatment, and 99 received study medication. Of 167 participants not allocated, 99 did not meet inclusion/met exclusion criteria, 3 were lost to follow-up, 14 withdrew consent, 1 experienced adverse events, and 50 were not allocated for other reasons (study termination).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Neridronic Acid - Treatment Period A</title>
          <description>Treatment Period A: Neridronic acid 100 mg - 4 intravenous infusions within 10 days; Follow-up Period 1 until 26 weeks.&#xD;
Treatment Period B: Neridronic acid 100 mg - 4 intravenous infusions within 10 days; Follow-up Period 2 until 52 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Placebo - Treatment Period A</title>
          <description>Treatment Period A: Matching placebo - 4 intravenous infusions within 10 days; Follow-up Period 1 until 26 weeks.&#xD;
Treatment Period B: Neridronic acid 100 mg - 4 intravenous infusions within 10 days; Follow-up Period 2 until 52 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Period A/Follow-up Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="51">One additional participant was allocated to placebo but not treated.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treatment Period A Completers</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disc. before end of Follow-up Period 1</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment Period B/Follow-up Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9">3 Participants completed Treatment Period A/Follow-up Period 1 but were not allocated in Period B.</participants>
                <participants group_id="P2" count="8">5 Part. completed Placebo Treatment Period A/Follow-up Period 1 but were not allocated in Period B.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treatment Period B Completers</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disc. before end of Follow-up Period 2</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Set; all participants treated in Treatment Period A.</population>
      <group_list>
        <group group_id="B1">
          <title>Neridronic Acid - Treatment Period A</title>
          <description>Neridronic acid 400 mg administered by 4 intravenous infusions within 10 Days in Treatment Period A.</description>
        </group>
        <group group_id="B2">
          <title>Placebo - Treatment Period A</title>
          <description>Matching placebo administered by 4 intravenous infusions within 10 Days in Treatment Period A.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="48"/>
            <count group_id="B2" value="51"/>
            <count group_id="B3" value="99"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.5" spread="12.7"/>
                    <measurement group_id="B2" value="50.4" spread="12.6"/>
                    <measurement group_id="B3" value="50.0" spread="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>&lt;18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>From 18 to &lt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>From 65 to &lt;85 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>85 years and above</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="71"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="86"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czechia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slovakia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CRPS type</title>
          <description>CRPS Type I: Occurs after a minor or major tissue injury without clinical signs of major peripheral nerve injury.&#xD;
CRPS Type II: Occurs after an injury with clinical signs of major peripheral nerve injury.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>CRPS Type I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CRPS Type II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown CRPS Type</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time since onset of CRPS symptoms</title>
          <units>months</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.88" lower_limit="7.30" upper_limit="18.90"/>
                    <measurement group_id="B2" value="11.80" lower_limit="6.00" upper_limit="18.57"/>
                    <measurement group_id="B3" value="12.33" lower_limit="6.63" upper_limit="18.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time since diagnosis of CRPS</title>
          <units>months</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.92" lower_limit="0.87" upper_limit="11.03"/>
                    <measurement group_id="B2" value="5.83" lower_limit="0.03" upper_limit="15.03"/>
                    <measurement group_id="B3" value="5.83" lower_limit="0.47" upper_limit="12.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to Week 12 in the Average Pain Intensity Score (Weekly Average of Pain Values Recorded Daily in the Electronic Diary)</title>
        <description>In the Baseline Phase and in Treatment Period A/Follow-up Period 1, participants were asked to assessed their average CRPS-related pain on an 11-point numerical rating scale (NRS) - from 0 = &quot;no pain&quot; to 10 = &quot;pain as bad as you can imagine&quot; and report it once daily (in the evening, 24-hour recall) in an electronic diary.&#xD;
Changes from baseline (average for the Baseline Phase) to the weekly average for Week 12 were calculated.</description>
        <time_frame>From the Baseline Phase (Day -7 to Day -1) to Week 12</time_frame>
        <population>Full Analysis Set; all participants treated in Treatment Period A with all data available at the time of last participant out following premature study termination.</population>
        <group_list>
          <group group_id="O1">
            <title>Neridronic Acid - Treatment Period A</title>
            <description>Neridronic acid 100 mg - 4 intravenous infusions within 10 Days</description>
          </group>
          <group group_id="O2">
            <title>Placebo - Treatment Period A</title>
            <description>Matching placebo - 4 intravenous infusions within 10 Days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 12 in the Average Pain Intensity Score (Weekly Average of Pain Values Recorded Daily in the Electronic Diary)</title>
          <description>In the Baseline Phase and in Treatment Period A/Follow-up Period 1, participants were asked to assessed their average CRPS-related pain on an 11-point numerical rating scale (NRS) - from 0 = &quot;no pain&quot; to 10 = &quot;pain as bad as you can imagine&quot; and report it once daily (in the evening, 24-hour recall) in an electronic diary.&#xD;
Changes from baseline (average for the Baseline Phase) to the weekly average for Week 12 were calculated.</description>
          <population>Full Analysis Set; all participants treated in Treatment Period A with all data available at the time of last participant out following premature study termination.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.28" spread="0.270"/>
                    <measurement group_id="O2" value="-1.71" spread="0.268"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Mixed-effects model for repeated measures (MMRM) defined with baseline pain intensity as covariate, the factors geographic region, week, treatment and treatment-by-week as fixed effects, and an unstructured covariance matrix to model the covariance structure of the repeated measurements.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2522</p_value>
            <p_value_desc>2-sided p-value for testing superiority of neridronic acid 400 mg compared to placebo.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The degrees of freedom of the denominator are estimated using the Kenward-Roger approximation.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.43</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.372</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.31</ci_lower_limit>
            <ci_upper_limit>1.17</ci_upper_limit>
            <estimate_desc>The primary endpoint estimate was the least squares mean differences of change from baseline in pain NRS (electronic diary) at Week 12 between neridronate and Placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 26 in the Average Pain Intensity Recorded on the Tablet Computer</title>
        <description>11-point NRS - from 0 = &quot;no pain&quot; to 10 = &quot;pain as bad as you can imagine&quot; - reported at the visits on a tablet computer (24-hour recall). Changes from baseline to Week 26 were planned to be analyzed.</description>
        <time_frame>From baseline (Visit 2 [Day 1]) to Visit 11 (Week 26)</time_frame>
        <population>Data were not collected or analyzed because a confirmatory testing strategy was not performed as pre-specified in the protocol that secondary endpoints would only be tested if neridronic acid was superior to placebo on the primary outcome measure. A confirmatory or descriptive analysis was not performed due to early study termination.</population>
        <group_list>
          <group group_id="O1">
            <title>Neridronic Acid - Treatment Period A</title>
            <description>Neridronic acid 100 mg - 4 intravenous infusions within 10 Days</description>
          </group>
          <group group_id="O2">
            <title>Placebo - Treatment Period A</title>
            <description>Matching placebo - 4 intravenous infusions within 10 Days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 26 in the Average Pain Intensity Recorded on the Tablet Computer</title>
          <description>11-point NRS - from 0 = &quot;no pain&quot; to 10 = &quot;pain as bad as you can imagine&quot; - reported at the visits on a tablet computer (24-hour recall). Changes from baseline to Week 26 were planned to be analyzed.</description>
          <population>Data were not collected or analyzed because a confirmatory testing strategy was not performed as pre-specified in the protocol that secondary endpoints would only be tested if neridronic acid was superior to placebo on the primary outcome measure. A confirmatory or descriptive analysis was not performed due to early study termination.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Response to Treatment, Defined as at Least 30% Decrease From Baseline in the Average Pain Intensity at Week 12, Recorded on the Tablet Computer</title>
        <description>11-point NRS - from 0 = &quot;no pain&quot; to 10 = &quot;pain as bad as you can imagine&quot; - reported at the visits on a tablet computer (24-hour recall).&#xD;
The number of participants with response at Week 12 was planned to be determined.</description>
        <time_frame>From baseline (Visit 2 [Day 1]) to Visit 8 (Week 12)</time_frame>
        <population>Data were not collected or analyzed because a confirmatory testing strategy was not performed as pre-specified in the protocol that secondary endpoints would only be tested if neridronic acid was superior to placebo on the primary outcome measure. A confirmatory or descriptive analysis was not performed due to early study termination.</population>
        <group_list>
          <group group_id="O1">
            <title>Neridronic Acid - Treatment Period A</title>
            <description>Neridronic acid 400 mg administered by 4 intravenous infusions within 10 Days in Treatment Period A.</description>
          </group>
          <group group_id="O2">
            <title>Placebo - Treatment Period A</title>
            <description>Matching placebo administered by 4 intravenous infusions within 10 Days in Treatment Period A.</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Response to Treatment, Defined as at Least 30% Decrease From Baseline in the Average Pain Intensity at Week 12, Recorded on the Tablet Computer</title>
          <description>11-point NRS - from 0 = &quot;no pain&quot; to 10 = &quot;pain as bad as you can imagine&quot; - reported at the visits on a tablet computer (24-hour recall).&#xD;
The number of participants with response at Week 12 was planned to be determined.</description>
          <population>Data were not collected or analyzed because a confirmatory testing strategy was not performed as pre-specified in the protocol that secondary endpoints would only be tested if neridronic acid was superior to placebo on the primary outcome measure. A confirmatory or descriptive analysis was not performed due to early study termination.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Response to Treatment, Defined as at Least 30% Decrease From Baseline in the Average Pain Intensity at Week 26, Recorded on the Tablet Computer</title>
        <description>11-point NRS - from 0 = &quot;no pain&quot; to 10 = &quot;pain as bad as you can imagine&quot; - reported at the visits on a tablet computer (24-hour recall). The number of participants with response at Week 26 was planned to be determined.</description>
        <time_frame>From baseline (Visit 2 [Day 1]) to Visit 11 (Week 26)</time_frame>
        <population>Data were not collected or analyzed because a confirmatory testing strategy was not performed as pre-specified in the protocol that secondary endpoints would only be tested if neridronic acid was superior to placebo on the primary outcome measure. A confirmatory or descriptive analysis was not performed due to early study termination.</population>
        <group_list>
          <group group_id="O1">
            <title>Neridronic Acid - Treatment Period A</title>
            <description>Neridronic acid 400 mg administered by 4 intravenous infusions within 10 Days in Treatment Period A.</description>
          </group>
          <group group_id="O2">
            <title>Placebo - Treatment Period A</title>
            <description>Matching placebo administered by 4 intravenous infusions within 10 Days in Treatment Period A.</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Response to Treatment, Defined as at Least 30% Decrease From Baseline in the Average Pain Intensity at Week 26, Recorded on the Tablet Computer</title>
          <description>11-point NRS - from 0 = &quot;no pain&quot; to 10 = &quot;pain as bad as you can imagine&quot; - reported at the visits on a tablet computer (24-hour recall). The number of participants with response at Week 26 was planned to be determined.</description>
          <population>Data were not collected or analyzed because a confirmatory testing strategy was not performed as pre-specified in the protocol that secondary endpoints would only be tested if neridronic acid was superior to placebo on the primary outcome measure. A confirmatory or descriptive analysis was not performed due to early study termination.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 12 in the Pain Intensity Level of Dynamic Mechanical Allodynia (DMA)</title>
        <description>Dynamic mechanical allodynia: a tactile stimulus is applied in a single sweeping motion (1 cm to 2 cm length) on the skin on the affected limb. The participants are asked to judge the stimulus intensity by means of an NRS (0 to 10). &quot;0&quot; in this case means &quot;no pain&quot;. Each &quot;pricking&quot;, &quot;stinging&quot; or &quot;burning&quot; sensation is defined as a painful sensation, which should always be evaluated by giving a value greater than &quot;0&quot;. &quot;10&quot; corresponds to the individual maximum pain imaginable. Change from baseline was planned to analyzed.</description>
        <time_frame>From baseline (Visit 2 [Day 1]) to Visit 8 (Week 12)</time_frame>
        <population>Data were not collected or analyzed because a confirmatory testing strategy was not performed as pre-specified in the protocol that secondary endpoints would only be tested if neridronic acid was superior to placebo on the primary outcome measure. A confirmatory or descriptive analysis was not performed due to early study termination.</population>
        <group_list>
          <group group_id="O1">
            <title>Neridronic Acid - Treatment Period A</title>
            <description>Neridronic acid 400 mg administered by 4 intravenous infusions within 10 Days in Treatment Period A.</description>
          </group>
          <group group_id="O2">
            <title>Placebo - Treatment Period A</title>
            <description>Matching placebo administered by 4 intravenous infusions within 10 Days in Treatment Period A.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 12 in the Pain Intensity Level of Dynamic Mechanical Allodynia (DMA)</title>
          <description>Dynamic mechanical allodynia: a tactile stimulus is applied in a single sweeping motion (1 cm to 2 cm length) on the skin on the affected limb. The participants are asked to judge the stimulus intensity by means of an NRS (0 to 10). &quot;0&quot; in this case means &quot;no pain&quot;. Each &quot;pricking&quot;, &quot;stinging&quot; or &quot;burning&quot; sensation is defined as a painful sensation, which should always be evaluated by giving a value greater than &quot;0&quot;. &quot;10&quot; corresponds to the individual maximum pain imaginable. Change from baseline was planned to analyzed.</description>
          <population>Data were not collected or analyzed because a confirmatory testing strategy was not performed as pre-specified in the protocol that secondary endpoints would only be tested if neridronic acid was superior to placebo on the primary outcome measure. A confirmatory or descriptive analysis was not performed due to early study termination.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 12 in the Pressure Pain Threshold (PPT) Ratio for the Thenar Muscle/Abductor Hallucis Muscle</title>
        <description>Pressure pain threshold: using a pressure algometer (contact area 1 cm2), the threshold for pressure-induced pain is measured on the thenar muscle/abductor hallucis muscle in 3 series of slowly increasing stimulus intensities (at a rate of about 50 kPa/s). The threshold is then determined as the arithmetic mean of the 3 series (in kPa).&#xD;
The ratio of the thresholds of the affected limb versus the unaffected limb was planned to be calculated.</description>
        <time_frame>From baseline (Visit 2 [Day 1]) to Visit 8 (Week 12)</time_frame>
        <population>Data were not collected or analyzed because a confirmatory testing strategy was not performed as pre-specified in the protocol that secondary endpoints would only be tested if neridronic acid was superior to placebo on the primary outcome measure. A confirmatory or descriptive analysis was not performed due to early study termination.</population>
        <group_list>
          <group group_id="O1">
            <title>Neridronic Acid - Treatment Period A</title>
            <description>Neridronic acid 400 mg administered by 4 intravenous infusions within 10 Days in Treatment Period A.</description>
          </group>
          <group group_id="O2">
            <title>Placebo - Treatment Period A</title>
            <description>Matching placebo administered by 4 intravenous infusions within 10 Days in Treatment Period A.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 12 in the Pressure Pain Threshold (PPT) Ratio for the Thenar Muscle/Abductor Hallucis Muscle</title>
          <description>Pressure pain threshold: using a pressure algometer (contact area 1 cm2), the threshold for pressure-induced pain is measured on the thenar muscle/abductor hallucis muscle in 3 series of slowly increasing stimulus intensities (at a rate of about 50 kPa/s). The threshold is then determined as the arithmetic mean of the 3 series (in kPa).&#xD;
The ratio of the thresholds of the affected limb versus the unaffected limb was planned to be calculated.</description>
          <population>Data were not collected or analyzed because a confirmatory testing strategy was not performed as pre-specified in the protocol that secondary endpoints would only be tested if neridronic acid was superior to placebo on the primary outcome measure. A confirmatory or descriptive analysis was not performed due to early study termination.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 12 in the Ratio of the Figure of Eight Measurements of the Affected Limb Versus the Unaffected Limb</title>
        <description>In participants with the CRPS sign of edema on the CRPS severity score at baseline, circumference of the hand or foot will be measured by the investigator with measurement tape using the figure-of-eight method at both the affected limb and the contralateral unaffected limb. Each measurement will be performed 3 times. The average of the 3 measurements will be used for further analysis.&#xD;
The ratio of the averages of the affected limb versus the unaffected limb was planned to be calculated and used for the determination of the change from baseline.</description>
        <time_frame>From baseline (Visit 2 [Day 1]) to Visit 8 (Week 12)</time_frame>
        <population>Data were not collected or analyzed because a confirmatory testing strategy was not performed as pre-specified in the protocol that secondary endpoints would only be tested if neridronic acid was superior to placebo on the primary outcome measure. A confirmatory or descriptive analysis was not performed due to early study termination.</population>
        <group_list>
          <group group_id="O1">
            <title>Neridronic Acid - Treatment Period A</title>
            <description>Neridronic acid 400 mg administered by 4 intravenous infusions within 10 Days in Treatment Period A.</description>
          </group>
          <group group_id="O2">
            <title>Placebo - Treatment Period A</title>
            <description>Matching placebo administered by 4 intravenous infusions within 10 Days in Treatment Period A.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 12 in the Ratio of the Figure of Eight Measurements of the Affected Limb Versus the Unaffected Limb</title>
          <description>In participants with the CRPS sign of edema on the CRPS severity score at baseline, circumference of the hand or foot will be measured by the investigator with measurement tape using the figure-of-eight method at both the affected limb and the contralateral unaffected limb. Each measurement will be performed 3 times. The average of the 3 measurements will be used for further analysis.&#xD;
The ratio of the averages of the affected limb versus the unaffected limb was planned to be calculated and used for the determination of the change from baseline.</description>
          <population>Data were not collected or analyzed because a confirmatory testing strategy was not performed as pre-specified in the protocol that secondary endpoints would only be tested if neridronic acid was superior to placebo on the primary outcome measure. A confirmatory or descriptive analysis was not performed due to early study termination.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were documented from the time of enrollment (i.e., the time the informed consent form was signed) up to the time of the last protocol scheduled contact, i.e., date of last visit/contact (could be a phone call, e.g., in case of withdrawal). Only treatment emergent adverse events (TEAEs, i.e., those reported from baseline (after first administration of study medication) are reported in the tables below.</time_frame>
      <desc>Participants with TEAEs may be presented in 2 of 6 reporting groups depending on the time the TEAEs were reported.&#xD;
Treatment Period A/Follow-up Period 1 (TPA): Baseline to Week 26 (Placebo or neridronic acid).&#xD;
Treatment Period B/Follow-up Period 2 (TPB): Week 26 to Week 52 (follow-up without study medication administration) or Week 26 to Week 52 (participants with neridronic acid treatment after placebo and those receiving re-treatment with neridronic acid).</desc>
      <group_list>
        <group group_id="E1">
          <title>Baseline to Week 26: Placebo TPA</title>
          <description>In Treatment Period A, participants received matching placebo - 4 intravenous infusions within 10 Days; Follow-up Period 1 until 26 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Baseline to Week 26: Neridronic Acid TPA</title>
          <description>In Treatment Period A, participants received neridronic acid 100 mg - 4 intravenous infusions within 10 days; Follow-up Period 1 until 26 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Week 26 to Week 52: Placebo TPA</title>
          <description>Participants with placebo treatment in Treatment Period A/Follow-up Period 1 were followed up without administration of study medication until 52 weeks in Follow-up Period 2.</description>
        </group>
        <group group_id="E4">
          <title>Week 26 to Week 52: Placebo TPA, Neridronic Acid TPB</title>
          <description>Participants who had completed treatment with placebo in Treatment Period A/Follow-up Period 1 received neridronic acid treatment (100 mg - 4 intravenous infusions within 10 days) in Treatment Period B/Follow-up Period 2 until 52 weeks.</description>
        </group>
        <group group_id="E5">
          <title>Week 26 to Week 52: Neridronic Acid TPA</title>
          <description>Participants who had completed treatment with neridronic acid treatment in Treatment Period A/Follow-up Period 1 were followed up without administration of study medication until 52 weeks in Follow-up Period 2.</description>
        </group>
        <group group_id="E6">
          <title>Week 26 to Week 52: Neridronic Acid TPA, Neridronic Acid TPB</title>
          <description>Participants who had completed treatment with neridronic acid in Treatment Period A/Follow-up Period 1 received re-treatment with neridronic acid 100 mg - 4 intravenous infusions within 10 days; Follow-up Period 2 until 52 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 22.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Silent myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysaesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 22.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="12" subjects_affected="8" subjects_at_risk="51"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="5" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="4" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Acute phase reaction</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="51"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="9" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Abscess neck</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Lyme disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Infection protozoal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Urine albumin/creatinine ratio increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Blood immunoglobulin G decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Vitamin D deficiency</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="51"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E2" events="8" subjects_affected="4" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Complex regional pain syndrome</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="51"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Taste disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="3" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor reserves the right to review any proposed full publication or poster or presentation of the results of this study by the coordinating or other investigator before they are submitted for publication or public disclosure. Neither the sponsor nor the coordinating investigator has the right to prohibit publication or public disclosure. Publication or public disclosure can be postponed for patent purposes.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>A pre-specified interim analysis was conducted on pooled primary endpoint data of studies KF7013-04 and KF7013-02 (NCT03530345). The interim analysis indicated futility (neridronate unlikely to be superior to placebo) and both studies were stopped.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Director Clinical Trials</name_or_title>
      <organization>Grünenthal GmbH</organization>
      <phone>+49 241 569 ext 3223</phone>
      <email>Clinical-Trials@grunenthal.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

